Having trouble accessing articles? Reset your cache.

Via Allergan hair loss deal, Exicure builds balance sheet to advance oncology, neurology pipeline

A collaboration deal giving Allergan options to obtain rights to Exicure's hair loss programs will provide the biotech with non-dilutive cash to further advance a pipeline of spherical nucleic acid (SNA) therapeutics for oncology,

Read the full 344 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers